Pharmaceutical Technology

JANUARY 22, 2024

Pneumococcal (23-valent) vaccine is under clinical development by Jiangsu Ab&b Bio-tech and currently in Phase I for Streptococcal Pneumonia.

Vaccination 100

Vaccination Vaccine Clinical Development Development 100

Pharmaceutical Technology

JANUARY 22, 2024

Pneumococcal (23-valent) vaccine is under clinical development by Jiangsu Ab&b Bio-tech and currently in Phase I for Streptococcal Pneumonia.

Vaccination 100

Vaccination Vaccine Clinical Development Development 100

Drug Discovery World

OCTOBER 14, 2022

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The post Merck and Moderna to develop a personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccination 97

Vaccination Vaccine Development Clinical Development 97

Drug Discovery World

MARCH 8, 2023

The first €7 million of this funding contributes to the development of the Phase II clinical study in Long Covid, the first results of which should be available by the end of this year.” The post €25 million to support clinical developments against Long Covid appeared first on Drug Discovery World (DDW).

Clinical Development 52

Clinical Development Development Vaccination Vaccine 52

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Innovative new vaccines are being created more rapidly than ever before.

Vaccination 97

Vaccination Vaccine Development Marketing 97

BioPharma Reporter

DECEMBER 5, 2022

Vaxxas has completed a financing round which raised US$23m (A$34m) in new funds: allowing the company to progress multiple vaccine programs in the clinic and ramp up manufacturing capabilities towards commercial scale.

Manufacturing 52

Manufacturing Clinical Development Vaccination Vaccine 52

Pharmaceutical Technology

OCTOBER 3, 2023

Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.

Vaccination 100

Vaccination Vaccine Clinical Development Development 100

VirTrial

OCTOBER 25, 2023

Vaccine studies can be large, multinational endeavors with sensitive timeframes, extended participation follow-up periods, multiphase designs, and critical data management needs. In recent years, Signant has been a part of more than 95 vaccine studies involving 140,000+ patients in more than 30 countries.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K. GAITHERSBURG, Md.,

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Drug Discovery World

FEBRUARY 27, 2024

New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease.

Vaccination 104

Vaccination Vaccine Antibody Clinical Trials 104

BioTech 365

DECEMBER 3, 2020

Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate Interim durability data from NIH-led Phase 1 study of mRNA-1273 published as … Continue reading →

Clinical Development 52

Clinical Development Production Vaccination Vaccine 52

Pharma Mirror

MARCH 29, 2022

NIEL, BELGIUM, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.

Manufacturing 130

Manufacturing Production Development RNA 130

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. The post New podcast: Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Development 59

Development Drugs Genome Genomics 59

Pharmaceutical Technology

JUNE 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.

Vaccination 147

Vaccination Vaccine Immune Response Clinical Trials 147

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report. Buy the report here.

Production 100

Production Vaccination Vaccine Immune Response 100

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report. Buy the report here.

Production 100

Production Vaccination Vaccine Immune Response 100

The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. He also led the expansion of Merck’s research and development in China and Japan. “It Eliav Barr, senior vice president, Global Clinical Development.

Clinical Development 52

Clinical Development Development Vaccination Vaccine 52

BioPharma Reporter

MARCH 8, 2021

Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.

Vaccination 138

Vaccination Vaccine Clinical Development Development 138

BioPharma Reporter

MARCH 3, 2021

Convergence towards common global standards for clinical trial application (CTA) rules, along with unilateral and mutual recognition of CTA approvals are some suggestions made by industry insiders in a new paper to enable robust and timely development of vaccines.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

XTalks

MARCH 1, 2021

(NYSE: PFE ) and BioNTech SE (Nasdaq: BNTX ) have announced that they are beginning a trial to evaluate the safety and efficacy of a third booster dose for their COVID-19 vaccine (BNT162b2), as well as new vaccine variants. Related: Could Pfizer and BioNTech’s COVID-19 Vaccine be Stored at Standard Freezer Temperatures?

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

XTalks

DECEMBER 13, 2023

This episode features an interview with vaccine scientists and executives from Vaccines Global Clinical Development at Merck, Dr. Heather Platt, MD, Distinguished Scientist and Pneumococcal Vaccine Lead; and Dr. Ulrike Buchwald, MD, Scientific Associate Vice President, Global Clinical Research and Pneumococcal Vaccine Section Head.

Life Science 52

Life Science Vaccination Vaccine Scientist 52

pharmaphorum

APRIL 19, 2021

The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . If you look at the development, we signed 15,000 people in six weeks in a trial set up by the NHS.

Vaccination 141

Vaccination Vaccine Manufacturing Clinical Development 141

BioPharma Reporter

AUGUST 13, 2020

CureVac files to raise upward of $200 million in Nasdaq IPO to fund clinical development of COVID-19 vaccine.

Vaccination 90

Vaccination Vaccine Development Clinical Development 90

pharmaphorum

MARCH 22, 2021

million grant from the European Commission to accelerate clinical development of mRNA therapies for hard-to-treat cancers. mRNA therapies have been in the spotlight since BioNTech and Pfizer used the technology to create a vaccine against COVID-19 last year. Belgian immunotherapy firm eTheRNA has received a €6.9

Vaccination 76

Vaccination Vaccine Development Trials 76

XTalks

OCTOBER 31, 2023

GlaxoSmithKline (GSK) Canada has roped in both older and younger versions of Wayne Gretzky for a new ad for its respiratory syncytial virus (RSV) vaccine Arexvy. The RSV vaccine ad has the now 62-year-old hockey legend looking into a mirror and seeing his younger self, specifically an AI-generated 20-year-old version of himself.

Vaccination 97

Vaccination Vaccine FDA Approval Development 97

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Development Immune Response 52

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. The post Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Development 52

Development Drugs Genome Genomics 52

BioPharma Reporter

APRIL 17, 2024

BSI, sat down with Liza Laws, the senior editor of OSP and BPR to discuss his companyâs pioneering work in revolutionizing vaccine adjuvant production. During DCAT this year, Gaston Saperi from Botanical Solutions Inc.,

Production 95

Production Vaccination Vaccine Clinical Development 95

Drug Discovery World

OCTOBER 24, 2023

One of the key presentations will be given by Dr Qasim Ahmad, Chief Medical Officer of IO Biotech, a Clinical Oncologist with two decades of strategic clinical development, medical affairs, and marketing authorisation expertise. Register for free to secure your place!

Vaccination 52

Vaccination Vaccine Research Clinical Development 52

BioTech 365

FEBRUARY 10, 2021

Giebel as Chairman to support its novel vaccine platform through accelerated clinical development SpyBiotech raises $32.5M SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. in Series A funding and appoints Lutz B. Giebel as Chairman to support … Continue reading →

Clinical Development 40

Clinical Development Vaccination Vaccine Development 40

BioSpace

SEPTEMBER 8, 2021

?The funds will be used to support further clinical development of VLP based vaccine candidate, HIL-214, to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection.

Vaccination 95

Vaccination Vaccine Clinical Development Development 95

pharmaphorum

FEBRUARY 10, 2022

AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted at the Beta variant of the virus, which started development before the emergence of the Delta and Omicron strains.

Vaccination 52

Vaccination Vaccine Development Immune Response 52

BioPharma Reporter

MARCH 28, 2022

A new study will seek to understand the bodyâs response to the Nipah virus in order to support development of vaccines.

Vaccination 52

Vaccination Vaccine Development Research 52

pharmaphorum

JULY 21, 2022

GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial virus (RSV) infections. ” The post Ex-GSK vaccine chief to lead new UK biotech Vicebio appeared first on. . ” He said.

Vaccination 105

Vaccination Vaccine Manufacturing Development 105

pharmaphorum

SEPTEMBER 4, 2020

Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK’s GSK to produce the vaccine, with Sanofi contributing an antigen that produces the immune reaction.

Clinical Trials 106

Clinical Trials Clinical Trials Vaccination Vaccine 106

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119